ArticleNeurocritical care2026
Induced Hypertension for Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage-A German Nationwide Survey.
Article in Neurocritical care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDelayed cerebral ischemia (DCI) remains a major cause of morbidity after aneurysmal subarachnoid hemorrhage (aSAH). Induced hypertension (IH) is frequently used to improve cerebral perfusion in patients with DCI, with current practice primarily supported by observational evidence with inconsistent guideline recommendations. We conducted a nationwide survey to assess current institutional approaches to IH in the management of DCI after aSAH in Germany.
methodsAn 11-item web-based questionnaire was distributed via LimeSurvey® between May and October 2025 to neurological and neurosurgical departments in Germany involved in the treatment of aSAH. The survey assessed institutional approaches to IH, monitoring and imaging strategies, and DCI treatment.
resultsOverall, 60/132 departments (45%) responded. IH was used by 56/59 departments (95%), predominantly in patients with suspected DCI (52/59, 88%). MAP-guided therapy was the most commonly applied IH strategy (64%), although hemodynamic targets varied substantially between departments. Noradrenaline was the primary vasopressor used for IH (98%). Transcranial doppler (TCD) ultrasonography was the predominant monitoring modality for DCI detection (93%), whereas advanced neuromonitoring techniques were used less frequently. Computed tomography (CT) perfusion (88%) and CT angiography (79%) were the most commonly applied imaging modalities in suspected DCI. IH alone (47%) or combined with intraarterial spasmolysis (36%) represented the leading first-line therapeutic approaches.
conclusionsIH remains a central component of DCI management after aSAH in Germany. Considerable variability regarding hemodynamic targets, monitoring strategies, imaging protocols, and therapeutic strategies highlights the absence of standardized evidence-based treatment approaches.
Indexed as
Identifiers
42625003What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.